MIRA Pharmaceuticals shares are trading higher after the company announced new preclinical data for Ketamir-2,
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals shares rose following the announcement of new preclinical data for their product Ketamir-2.
September 27, 2024 | 6:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MIRA Pharmaceuticals' stock price increased due to the release of promising preclinical data for Ketamir-2, indicating potential future success for the product.
The announcement of new preclinical data for Ketamir-2 is a positive development for MIRA Pharmaceuticals, suggesting potential future success and driving investor interest, leading to a rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100